Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

http://www.businessweek.com/ap/2014-02-11/sprint-and-annies-are-big-market-movers

AP News

Sprint and Annie's are big market movers


NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:

NYSE

Dean Foods Co., down $1.12 to $14.08

The nation's largest milk processor said that high commodity prices will make 2014 a challenging year.

ConAgra Foods Inc., down $1.97 to $29.08

The food products company trimmed its outlook for 2014 and 2015 on low volumes, margin pressure and soft sales for private brands.

Reynolds American Inc., down 74 cents to $48.07

Quarterly profit spiked as higher prices and lower legal costs offset falling sales at the nation's second-biggest tobacco company.

Sprint Corp., up 21 cents to $7.90

Fourth-quarter losses were contained at the third-largest U.S. wireless carrier as it added more devices to its network.

Annie's Inc., down $3.62 to $38.21

The rising price of organic wheat for the organic foods maker will weight on profits this year, at least in the first half.

Nasdaq

Groupon Inc., down 68 cents to $10.40

The departure of a key product executive spooked investors, though most analysts say the online deals site has a deep bench.

Allscripts Healthcare Solutions Inc., up 46 cents to $16.68

Analysts with the Maxim Group tagged the electronic health records company with a "Buy," rating citing its turnaround efforts.

Cadence Pharmaceuticals Inc., up $2.93 to $14

Mallinckrodt is buying the pharmaceutical company for about $1.21 billion in a bid to strengthen its specialty drugs unit.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus